Context Therapeutics
3001 Market Street
Suite 140
Philadelphia
Pennsylvania
19104
United States
Tel: 484-451-8601
Website: http://www.contexttherapeutics.com/
Email: info@contexttherapeutics.com
About Context Therapeutics
Context is advancing a novel path to treating diseases by targeting Sigma1, a key regulator of mechanisms and pathways that drive cellular protein homeostasis and immune system regulation.YEAR FOUNDED:
2016
LEADERSHIP:
Co-Founder & CEO: Martin Lehr
Co-Founder & CSO: Felix Kim, PhD
CMO: Erard Gilles, MD, MSc
SCIENCE:
Please click here for Context's science.
65 articles about Context Therapeutics
-
Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers
4/1/2024
Context Therapeutics Inc. Today announced that on March 28, 2024, the Company submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration to begin a first-in-human clinical study of CTIM-76.
-
Context Therapeutics Reports Full Year 2023 Operating and Financial Results
3/21/2024
Context Therapeutics Inc. today announced its financial results for the year ended December 31, 2023.
-
Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results
11/9/2023
Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced its financial results for the third quarter ended September 30, 2023, and reported on recent and upcoming business highlights.
-
Context Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76
10/31/2023
Context Therapeutics Inc. today announced encouraging preclinical data regarding the Company’s preclinical asset, CTIM-76, a Claudin 6 (CLDN6) x CD3 T-cell engaging bispecific antibody.
-
Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
9/27/2023
Context Therapeutics Inc. announced a poster regarding the Company’s preclinical asset, CTIM-76, a Claudin 6 x CD3 bispecific antibody will be presented at the Society for Immunotherapy of Cancer’s 38th Annual Meeting taking place November 3-5, 2023, at the San Diego Convention Center in San Diego, CA.
-
Context Therapeutics Reports Second Quarter 2023 Operating and Financial Results
8/9/2023
Context Therapeutics Inc., a biopharmaceutical company advancing medicines for solid tumors, announced its financial results for the second quarter ended June 30, 2023, and reported on recent and upcoming business highlights.
-
Context Therapeutics to Participate in Two August 2023 Investor Conferences
8/1/2023
Context Therapeutics Inc. today announced that Chief Executive Officer Martin Lehr will participate virtually in two investor conferences in August 2023.
-
ASCO 2023 Spotlight: Claudin 6 Anticipated To Shine
5/17/2023
The escalating battle between Claudin 6 immunotherapies from Amgen, BioNTech and Context Therapeutics, and CLDN6 antibody-drug-conjugates from Daiichi-Sankyo and TORL BioTherapeutics will be a highlight of the upcoming 2023 American Society of Clinical Oncology Annual Meeting, taking place on June 2-6, 2023, in Chicago, IL.
-
Context Therapeutics Reports First Quarter 2023 Operating and Financial Results
5/10/2023
Context Therapeutics Inc., a biopharmaceutical company dedicated to improving the lives of patients living with cancer, announced its financial results for the first quarter ended March 31, 2023, and reported on recent and upcoming business highlights.
-
Context Therapeutics to Participate in Two April 2023 Investor Conferences
4/3/2023
Context Therapeutics Inc., a biopharmaceutical company developing novel treatments for solid tumors, announced that Chief Executive Officer Martin Lehr will participate virtually in two investor conferences in April 2023.
-
Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates
3/22/2023
Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company developing novel treatments for solid tumors, today announced financial results for the year ended December 31, 2022.
-
Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023
3/15/2023
Context Therapeutics Inc. today announced that an abstract regarding Context’s preclinical candidate, CTIM-76, a Claudin 6 x CD3 bispecific antibody, has been selected for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023.
-
Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer
2/6/2023
Context Therapeutics Inc. today announced that two patients have achieved a confirmed partial response (PR) among the first 12 patients (9 evaluable) enrolled in the Phase 2 OATH clinical trial evaluating the potential of Context’s oral progesterone receptor antagonist onapristone extended release (ONA-XR) in combination with anastrozole (ANA) to treat hormone receptor positive (HR+) metastatic endometrial cancer (EC).
-
Context Therapeutics’ Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer
1/31/2023
Context Therapeutics Inc. today announced that its clinical trial collaborator, Stemline Therapeutics, Inc., a wholly owned subsidiary of The Menarini Group (“Menarini”), received approval from the U.S. Food and Drug Administration (FDA) for ORSERDU.
-
Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers
1/9/2023
Context Therapeutics Inc. and Lonza today announced that the companies are collaborating to manufacture CTIM-76, Context’s clinical development candidate.
-
Integral Molecular Reveals Mechanism Underlying Exquisite Specificity of Claudin 6 Therapeutic Antibody Being Developed for Solid Tumors
1/5/2023
Integral Molecular, the industry leader in antibody discovery for membrane proteins, has published the targeting mechanism enabling best-in-class specificity of its Claudin 6 antibody CTIM-76 being developed for cancer therapy with Context Therapeutics.
-
Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones
1/4/2023
Context Therapeutics Inc. provided 2022 year-end updates and corporate guidance for 2023.
-
Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer
12/8/2022
Context Therapeutics Inc. announced preliminary Phase 2 data from the ongoing SMILE trial of onapristone extended release (ONA-XR), the company’s novel, first-in-class, potent, orally administered progesterone receptor (PR) antagonist, in metastatic breast cancer.
-
Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors
11/29/2022
Context Therapeutics Inc. today announced the selection of CTIM-76, a T cell-engaging bispecific antibody, as its lead clinical development candidate to target Claudin 6 (CLDN6) positive cancers, resulting from its research collaboration and licensing agreement with Integral Molecular.
-
Context Therapeutics® Announces Clinical Updates on ONA-XR to be Presented at 2022 San Antonio Breast Cancer Symposium
11/21/2022
Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing novel treatments for breast and gynecologic cancers, today announced clinical data on onapristone extended release (ONA-XR) will be presented at the 2022 San Antonio Breast Cancer Symposium® (SABCS®) taking place in San Antonio, Texas, from December 6-10, 2022.